Design of a protective single-dose intranasal nanoparticle-based vaccine platform for respiratory infectious diseases

Bret D. Ulery, Devender Kumar, Amanda E. Ramer-Tait, Dennis W. Metzger, Michael J. Wannemuehler, Balaji Narasimhan

Research output: Contribution to journalArticle

81 Citations (Scopus)

Abstract

Despite the successes provided by vaccination, many challenges still exist with respect to controlling new and re-emerging infectious diseases. Innovative vaccine platforms composed of adaptable adjuvants able to appropriately modulate immune responses, induce long-lived immunity in a single dose, and deliver immunogens in a safe and stable manner via multiple routes of administration are needed. This work describes the development of a novel biodegradable polyanhydride nanoparticle-based vaccine platform administered as a single intranasal dose that induced long-lived protective immunity against respiratory disease caused by Yesinia pestis, the causative agent of pneumonic plague. Relative to the responses induced by the recombinant protein F1-V alone and MPLA-adjuvanted F1-V, the nanoparticle-based vaccination regimen induced an immune response that was characterized by high titer and high avidity IgG1 anti-F1-V antibody that persisted for at least 23 weeks post-vaccination. After challenge, no Y. pestis were recovered from the lungs, livers, or spleens of mice vaccinated with the nanoparticle-based formulation and histopathological appearance of lung, liver, and splenic tissues from these mice post-vaccination was remarkably similar to uninfected control mice.

Original languageEnglish (US)
Article numbere17642
JournalPloS one
Volume6
Issue number3
DOIs
StatePublished - Mar 10 2011

Fingerprint

Pulmonary diseases
nanoparticles
Nanoparticles
infectious diseases
Communicable Diseases
Vaccination
Vaccines
vaccination
vaccines
Liver
Polyanhydrides
lungs
dosage
Immunity
mice
immunity
immune response
Emerging Communicable Diseases
Recombinant Proteins
Lung

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)
  • General

Cite this

Design of a protective single-dose intranasal nanoparticle-based vaccine platform for respiratory infectious diseases. / Ulery, Bret D.; Kumar, Devender; Ramer-Tait, Amanda E.; Metzger, Dennis W.; Wannemuehler, Michael J.; Narasimhan, Balaji.

In: PloS one, Vol. 6, No. 3, e17642, 10.03.2011.

Research output: Contribution to journalArticle

Ulery, Bret D. ; Kumar, Devender ; Ramer-Tait, Amanda E. ; Metzger, Dennis W. ; Wannemuehler, Michael J. ; Narasimhan, Balaji. / Design of a protective single-dose intranasal nanoparticle-based vaccine platform for respiratory infectious diseases. In: PloS one. 2011 ; Vol. 6, No. 3.
@article{749cf5df61854761a96b23717bdc0bd1,
title = "Design of a protective single-dose intranasal nanoparticle-based vaccine platform for respiratory infectious diseases",
abstract = "Despite the successes provided by vaccination, many challenges still exist with respect to controlling new and re-emerging infectious diseases. Innovative vaccine platforms composed of adaptable adjuvants able to appropriately modulate immune responses, induce long-lived immunity in a single dose, and deliver immunogens in a safe and stable manner via multiple routes of administration are needed. This work describes the development of a novel biodegradable polyanhydride nanoparticle-based vaccine platform administered as a single intranasal dose that induced long-lived protective immunity against respiratory disease caused by Yesinia pestis, the causative agent of pneumonic plague. Relative to the responses induced by the recombinant protein F1-V alone and MPLA-adjuvanted F1-V, the nanoparticle-based vaccination regimen induced an immune response that was characterized by high titer and high avidity IgG1 anti-F1-V antibody that persisted for at least 23 weeks post-vaccination. After challenge, no Y. pestis were recovered from the lungs, livers, or spleens of mice vaccinated with the nanoparticle-based formulation and histopathological appearance of lung, liver, and splenic tissues from these mice post-vaccination was remarkably similar to uninfected control mice.",
author = "Ulery, {Bret D.} and Devender Kumar and Ramer-Tait, {Amanda E.} and Metzger, {Dennis W.} and Wannemuehler, {Michael J.} and Balaji Narasimhan",
year = "2011",
month = "3",
day = "10",
doi = "10.1371/journal.pone.0017642",
language = "English (US)",
volume = "6",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "3",

}

TY - JOUR

T1 - Design of a protective single-dose intranasal nanoparticle-based vaccine platform for respiratory infectious diseases

AU - Ulery, Bret D.

AU - Kumar, Devender

AU - Ramer-Tait, Amanda E.

AU - Metzger, Dennis W.

AU - Wannemuehler, Michael J.

AU - Narasimhan, Balaji

PY - 2011/3/10

Y1 - 2011/3/10

N2 - Despite the successes provided by vaccination, many challenges still exist with respect to controlling new and re-emerging infectious diseases. Innovative vaccine platforms composed of adaptable adjuvants able to appropriately modulate immune responses, induce long-lived immunity in a single dose, and deliver immunogens in a safe and stable manner via multiple routes of administration are needed. This work describes the development of a novel biodegradable polyanhydride nanoparticle-based vaccine platform administered as a single intranasal dose that induced long-lived protective immunity against respiratory disease caused by Yesinia pestis, the causative agent of pneumonic plague. Relative to the responses induced by the recombinant protein F1-V alone and MPLA-adjuvanted F1-V, the nanoparticle-based vaccination regimen induced an immune response that was characterized by high titer and high avidity IgG1 anti-F1-V antibody that persisted for at least 23 weeks post-vaccination. After challenge, no Y. pestis were recovered from the lungs, livers, or spleens of mice vaccinated with the nanoparticle-based formulation and histopathological appearance of lung, liver, and splenic tissues from these mice post-vaccination was remarkably similar to uninfected control mice.

AB - Despite the successes provided by vaccination, many challenges still exist with respect to controlling new and re-emerging infectious diseases. Innovative vaccine platforms composed of adaptable adjuvants able to appropriately modulate immune responses, induce long-lived immunity in a single dose, and deliver immunogens in a safe and stable manner via multiple routes of administration are needed. This work describes the development of a novel biodegradable polyanhydride nanoparticle-based vaccine platform administered as a single intranasal dose that induced long-lived protective immunity against respiratory disease caused by Yesinia pestis, the causative agent of pneumonic plague. Relative to the responses induced by the recombinant protein F1-V alone and MPLA-adjuvanted F1-V, the nanoparticle-based vaccination regimen induced an immune response that was characterized by high titer and high avidity IgG1 anti-F1-V antibody that persisted for at least 23 weeks post-vaccination. After challenge, no Y. pestis were recovered from the lungs, livers, or spleens of mice vaccinated with the nanoparticle-based formulation and histopathological appearance of lung, liver, and splenic tissues from these mice post-vaccination was remarkably similar to uninfected control mice.

UR - http://www.scopus.com/inward/record.url?scp=79952285914&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952285914&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0017642

DO - 10.1371/journal.pone.0017642

M3 - Article

C2 - 21408610

AN - SCOPUS:79952285914

VL - 6

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 3

M1 - e17642

ER -